The Center for Biosimilars® recaps the top news for the week of April 22, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 22.
Number 5: The FDA has granted priority review to Novartis’ innovator biologic, brolucizumab, which outperformed aflibercept in some secondary study endpoints.
Number 4: Xbrane Biopharma, a Swedish biotechnology company, says it is starting its phase 3 trial of its ranibizumab biosimilar, and set sales targets for the drug.
Number 3: A new paper explains that disparities in access to biologics are still frequent in Europe, but biosimilars could help.
Number 2: A new survey revealed managed care and specialty pharmacy professionals’ perceptions about overcoming challenges to biosimilars.
Number 1: As biosimilars begin to gain ground in Canada, Janssen has launched a program that it says will offer patients brand-name biologics at prices similar to those of biosimilar options.
Finally, last week, our e-newsletter asked whether you think that an advocacy group’s recent recommendation (that patients who are being successfully treated should not be switched to biosimilars) is justified.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.